OncoZenge
5.36
SEK
+6.56 %
Less than 1K followers
ONCOZ
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
+6.56%
+19.78%
-14.1%
+42.93%
+25.97%
+53.14%
+85.15%
-
-56.2%
OncoZenge is a Swedish pharmaceutical company that develops treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. After completing phase 2 studies, the company's product candidate is under further development as a basis for applying for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.
Read moreMarket cap
62.78M SEK
Turnover
442.98K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
21.8
2025
Interim report Q2'25
20.11
2025
Interim report Q3'25
All
Press releases
ShowingAll content types
Redeye: OncoZenge Q1 - Pieces falling into place
OncoZenge AB: OncoZenge: Investor Receives NDRC Approval
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools